Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient.

pembrolizumab 治疗的非小细胞肺癌患者的严重上消化道疾病。

• 发表时间: Aug 2018
• 来源期刊: Respirol Case Rep
• DOI: 10.1002/rcr2.334
• PMID: 30065841
• 文章类型: Case Reports
• 作者列表: Onuki T,Morita E,Sakamoto N,Nagai Y,Sata M,Hagiwara K

关键词: Immune checkpoint inhibitor; immune‐related adverse events; non‐small cell lung cancer; pembrolizumab; upper gastrointestinal disorder

Abstract

Pembrolizumab is an immune checkpoint inhibitor that induces side effects called \"immune-related adverse events\" (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non-small cell lung cancer.

摘要

Pembrolizumab是一种免疫检查点抑制剂，可诱导称为“免疫相关不良事件”（irAE）的副作用。各种类型的器官都受到irAE的影响，尽管上消化道疾病的报道很少见。这里,我们报告了一例食管广泛的炎症性病变，胃,十二指肠,和空肠在给予派姆单抗治疗非小细胞肺癌后。